Shots:
- The US FDA has approved Ion Torrent Oncomine Dx Target Test as a companion diagnostic to identify pts with NSCLC harboring HER2/ERBB2 TKD activating mutations
- Oncomine Dx Target allows clinicians to identify pts eligible for treatment with Bayer’s HER2-directed therapy Hyrnuo (sevabertinib) for locally advanced or metastatic non-squamous NSCLC
- Oncomine Dx Target Test, first FDA-approved in 2017 as an NGS companion diagnostic, has gained approvals in 20 countries for 11 biomarkers & 20+ targeted therapies, & in the US is authorized for use with multiple therapies across NSCLC & other tumor types
Ref: Bussinesswire| Image: ThermoFisher| Press Release
Related News:- Xcell Biosciences and ThermoFisher Enter Into a Joint Research Collaboration to Advance Cell Therapies
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
